



Second Quarter 2024

Earnings Highlights

\$13.3B

Revenue

+3% Op¹ Growth

+14% Op Growth excl. COVID-19 products

\$0.01

Rep. Dil. EPS²

-98% Decline

\$0.60

Adj. Dil. EPS³

-10% Op Decline

\$4.8B

Cash Dividends Returned to Shareholders H1 2024

\$0.84 Per Share of Common Stock

\$2.7B

Rep. R&D Expenses

+2% Op Growth

FY 2024 Guidance⁴

\$59.5B-\$62.5B

Revenue

\$2.45-\$2.65

Adj. Dil. EPS³

"I am encouraged by our performance in the first half of 2024 and we remain focused on making a difference in the lives of patients as we continue to advance and strengthen our company."

Albert Bourla

Chairman and Chief Executive Officer



Second-Quarter 2024 Global Pharmaceutical Revenues

Primary Care

\$5.0B Revenue

-15% Op Decline

Specialty Care

\$4.1B Revenue

+14% Op Growth

Oncology

\$4.0B Revenue

+27% Op Growth

Key Revenue Growth Drivers

Legacy

Seagen
Portfolio

Vyndaqel
Family

Eliquis⁶
(apixaban) tablets 5mg, 2.5mg

Nurtec ODT **Vydura** 75mg

Pipeline Spotlights⁷

Approved in EU
DURVEQTIX⁸

Treatment of severe and moderately severe hemophilia B in adults without a history of factor IX inhibitors and without detectable antibodies to variant AAV serotype Rh74.

LORBRENA
LORLATINIB 125

Presented 5-year follow-up Phase 3 results for previously untreated, ALK-positive advanced non-small cell lung cancer.

ADCETRIS
brentuximab vedotin 100mg/100mg

Presented Phase 3 overall survival results for investigational treatment of patients with relapsed/refractory diffuse large B-cell lymphoma as combination therapy; U.S. regulatory filing accepted for review.

ADCETRIS
brentuximab vedotin 100mg/100mg

Announced 4-year results from Phase 3 HD21 trial of combination treatment regimen in newly diagnosed Stage IIb/III/IV classical Hodgkin lymphoma.

ELREXFIO
(elranatamab-bcmm)

Presented Phase 2 overall survival results for treatment of patients with heavily pretreated relapsed or refractory multiple myeloma.

Candidate
Giroctocogene fitelparvovec

Announced positive Phase 3 topline results for the treatment of adults with moderately severe to severe hemophilia A.

Candidate
Danuglipron

Advanced development of once-daily modified release formulation of oral glucagon-like peptide-1 receptor agonist for obesity.

>192M Patients Impacted

YTD Q2 2024 with our medicines and vaccines⁹



2024 Key Priorities

Focused on executing with excellence against strategic goals to drive long-term growth



Achieve

world-class oncology leadership



Deliver

next wave of pipeline innovation



Maximize

performance of new products



Expand

margins by realigning cost base



Allocate

capital to enhance shareholder value

What's Next

Remains confident in ability to deliver operational growth and meaningful shareholder value long term.



Maintain

patient centricity



Scale

emerging tech platforms



Invest

in areas we can win



Foster

a culture of innovation




Reduce

approval development cycle times

ANTICIPATES

Non-COVID 2024 operational revenue growth of 9 to 11%⁹



investors.pfizer.com

Please reference Pfizer's Q2 2024 earnings release and SEC filings for additional information.

¹ Reference to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates.

² Second-quarter 2024 Reported diluted EPS was unfavorably impacted by \$0.18 resulting from a \$1.3 billion one-time restructuring charge related to the Manufacturing Optimization Program announced on Form 8-K on May 22, 2024.

³ Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP net income attributable to Pfizer Inc. common shareholders and U.S. GAAP diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. See the reconciliations of certain GAAP Reported to Non-GAAP Adjusted information for the second quarter and first six months of 2024 and 2023 accompanying Pfizer's earnings release furnished with Pfizer's Current Report on Form 8-K dated July 30, 2024. Adjusted income and its components and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. See the Non-GAAP Financial Measures: Adjusted Income section of Management's Discussion and Analysis of Financial Condition and Results of Operations in Pfizer's 2023 Annual Report on Form 10-K and the Non-GAAP Financial Measure: Adjusted Income section accompanying Pfizer's earnings release furnished with Pfizer's Current Report on Form 8-K dated July 30, 2024, for additional information.

⁴ Total company guidance. Please see Pfizer's Q2 2024 earnings release for additional details and assumptions regarding Pfizer's 2024 financial guidance.

⁵ Vynndaqel family includes global revenues from Vynndaqel, as well as revenues for Vynnamax in the U.S. and Vynmac in Japan.

⁶ Primarily reflects alliance revenues and product revenues.

⁷ Pipeline updates as of July 30, 2024.

⁸ The Patients Impacted metric is calculated from Pfizer and third-party datasets. Figures may be limited given the coverage provided by external sources (e.g., calendar duration, geographic and product coverage) and are subject to change. Numbers are estimates and in some cases use global volume, daily dosage and number of treatment days to facilitate calculations. Methodologies to calculate estimates may vary by product type given the nature of the product and available data. Patients taking multiple Pfizer products may be counted as multiple patients towards total. Numbers do not include comprehensive estimated patient counts from Ex-U.S. Access & Affordability programs. Historical estimates may periodically be subject to revision due to restatements in the underlying data source.

⁹ Please see Pfizer's Q2 2024 earnings release for additional details and assumptions regarding Pfizer's 2024 financial guidance.

This document includes forward-looking statements about, among other things, Pfizer's anticipated operating and financial performance, including financial guidance and projections, product pipeline, in-line products and product candidates, product launches, revenue contributions, business plans, strategy, goals and prospects, growth potential, business development activities, manufacturing and product supply, capital allocation objectives, dividends and share repurchases that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to Pfizer's Annual Report on Form 10-K for the year ended December 31, 2023, and Pfizer's subsequent reports on Form 10-Q, including the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results," as well as Pfizer's subsequent reports on Form 8-K for a description of the substantial risks and uncertainties related to the forward-looking statements included in this document. These reports are available on Pfizer's website at www.pfizer.com and on the U.S. Securities and Exchange Commission's website at www.sec.gov. The forward-looking statements in this document speak only as of the original date of this document, and we undertake no obligation to update or revise any of these statements.